Company: INKT
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001193125-25-282905
Chunk: 8

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 5
Chunk 8
---
Trading Plans of Our Directors and Officers

During the quarter ended September 30, 2025, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.

Departure of Principal Accounting Officer

On November 11, 2025, Christine M. Klaskin, Treasurer, Principal Financial Officer, and Principal Accounting Officer of the Company, informed the Company she will be retiring effective December 31, 2025. Ms. Klaskin will continue as a consultant to the Company.